Powered by
ANN ARBOR–Officials at Esperion Therapeutics Inc. (Nasdaq: ESPR) announced record revenue in the second quarter ended June 30, as its cholesterol-fighting drugs Nexletol and Nexlizet have been approved for use …
ANN ARBOR—Millendo Therapeutics Inc. (Nasdaq: MLND), a pharmaceutical startup developing new drugs for endocrine diseases, announced that it had engaged SVB Leerink, a Boston-based investment bank, in a “strategic review …
CANTON TWP.—The life sciences regulatory and clinical data consultant MMS Holdings announced it had been retained by Thunder Bay, Ontario-based IGY Life Sciences to further the development of IgY-110, an …
ANN ARBOR—Esperion Therapeutics Inc. (NASDAQ: ESPR), developers of novel treatments to reduce cholesterol in the bloodstream, announced the United States commercial availability of Nexlizet tablets. Nexlizet is a combination of …
ANN ARBOR—BlueWillow Biologics, a firm founded in 1999 that is developing nanotechnology for healthcare applications, announced the availability of NanoBio Protect on Amazon. NanoBio Protect is an alcohol-free antiseptic solution that …
ANN ARBOR—Millendo Therapeutics Inc. (Nasdaq:MLND), a clinical stage biopharmaceutical company developing novel treatments for endocrine diseases with significant unmet needs, reported a loss of $12 million or 65 cents per …
ANN ARBOR—Esperion Therapeutics Inc. (NASDAQ:ESPR) reported a loss of $78.2 million or $2.84 a share in the first quarter of 2020, vs. net income of $87.4 million or $3.07 a …
CANTON TWP.—MMS Holdings Inc. said that its collaboration with Shanghai-based Green Valley Pharmaceutical Co. resulted in gaining U.S. Food & Drug Administration approval of an Investigational New Drug application for …
ANN ARBOR—Esperion Therapeutics Inc. announced a collaboration agreement with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of Nexletol and Nexlizet tablets in Japan. Both medicines were recently approved …
DETROIT—An oral therapy that has been studied in laboratory experiments and clinical trials at the Barbara Ann Karmanos Cancer Institute, in partnership with Karyopharm Therapeutics Inc., will soon enter clinical …